X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Gimoti (metoclopramide) increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Gimoti (metoclopramide) nasal spray is a dopamine receptor antagonist to treat nausea and vomiting in patients with gastroesophageal reflux disease or diabetic gastroparesis by increasing movements or contractions of the stomach and intestines.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
GIMOTI (metoclopramide) is a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder in which the stomach takes too long to empty its contents.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
GIMOTI is the first and only FDA-approved novel nasal formulation of metoclopramide that is commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
GIMOTI (metoclopramide) is first and only FDA-approved nasal formulation of metoclopramide that is commercially available and specifically designed to deliver non-oral dose of metoclopramide for relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
GIMOTI, a nasal spray formulation of metoclopramide, is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
Gimoti (metoclopramide) nasal spray, is a dopamine-2 (D2) antagonist is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Details:
Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with Gimoti (metoclopramide).
Lead Product(s): Metoclopramide
Therapeutic Area: Neurology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
GIMOTI, a nasal spray formulation of metoclopramide, for relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults, 100% of current GIMOTI users report seeing at least some symptom improvement; diminished nausea is most cited symptom improvement.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
